ResearcherMayo ClinicNo recent work listed
Brooke L. Fridley
Matched on ORCID iD 0000-0001-7739-7956; OpenAlex author ID A5004055647; NIH RePORTER profile ID 8895208. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 2, last author 0)
- Trials
- 0
- Grants
- 1
- Labs led
- 2
- Collaborators
- 8
2011: 1 paper · 2012: 1 grant · 2013: 2 papers · 2014: none · 2015: none · 2016: 1 paper
Papers 4
- Genetic variations associated with gemcitabine treatment outcome in pancreatic cancer. Co-author DOI 10.1097/fpc.0000000000000241↗
- Survival is associated with genetic variation in inflammatory pathway genes among patients with resected and unresected pancreatic cancer. First author DOI 10.1097/sla.0b013e318275b7e5↗
- Contribution of FKBP5 genetic variation to gemcitabine treatment and survival in pancreatic adenocarcinoma. Co-author DOI 10.1371/journal.pone.0070216↗
- Inflammation-related gene variants as risk factors for pancreatic cancer. First author DOI 10.1158/1055-9965.epi-11-0264↗
Grants 1
Closest collaborators
The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Gloria M. Petersen · 4 shared papers, 2011–2016 · strength 0.16
- Paper Genetic variations associated with gemcitabine treatment outcome in pancreatic cancer. DOI 10.1097/fpc.0000000000000241↗
- Paper Survival is associated with genetic variation in inflammatory pathway genes among patients with resected and unresected… DOI 10.1097/sla.0b013e318275b7e5↗
- Paper Contribution of FKBP5 genetic variation to gemcitabine treatment and survival in pancreatic adenocarcinoma. DOI 10.1371/journal.pone.0070216↗
- Liewei Wang · 2 shared papers, 2013–2016 · strength 0.09
- Liang Li · 2 shared papers, 2013–2016 · strength 0.09
- Kaye M. Reid–Lombardo · 2 shared papers, 2011–2013 · strength 0.07
- Michael G. Sarr · 2 shared papers, 2011–2013 · strength 0.07
- Jianwei Zhang · 1 shared paper, 2016 · strength 0.06
- Robert R. McWilliams · 1 shared paper, 2016 · strength 0.06
- Katarzyna A. Ellsworth · 1 shared paper, 2013 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.